JP Morgan initiated coverage on Blueprint Medicines Corporation (NASDAQ:BPMC), a biotech company focused on modulating immune ...
JPMorgan initiated coverage of Blueprint Medicines (BPMC) with an Overweight rating and $126 price target Blueprint is a biotech company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback